^
    Back
    Association details:
    Biomarker:LRP1B mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Targeted sequencing analysis of predominant histological subtypes in resected stage I invasive lung adenocarcinoma.

    Published date:
    05/29/2020
    Excerpt:
    ...LRP1B mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p = 0.001)….showed that SPA patients harboring LRP1B mutations may benefit from immunotherapy.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21067